NCT03195569

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 15 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer

Detailed description

The study is QL1101-002 additional research, by detecting the blood circulating endothelial cells and blood perfusion parameters change within tumors early prediction efficacy and drug resistance.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	QL1101	targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
DRUG	Avastin®	targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
DRUG	Paclitaxel	175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
DRUG	Carboplatin	AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.

Timeline

• Start date: 2017-03-01
• Primary completion: 2018-06-12
• Completion: 2018-12-10
• First posted: 2017-06-22
• Last updated: 2017-06-22

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study